Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The “underappreciated” partnership opportunity with Roche (RHHBY) creates a “compelling entry point,” the analyst tells investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma completes enrollment in ZUPREME-1 trial
- Zealand Pharma upgraded to Buy from Hold at SEB Equities
- Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
- William Blair upgrades Zealand to Outperform on recent selloff
- Zealand Pharma upgraded to Outperform from Market Perform at William Blair